Volume 8, Number 5—May 2002
Research
Excess Mortality Associated with Antimicrobial Drug-Resistant Salmonella Typhimurium
Morten Helms*, Pernille Vastrup*, Peter Gerner-Smidt*, and Kåre Mølbak*
Table 1
The distribution of comorbidity diagnosis of 2,047 patients with S. Typhimurium infection and a sample of the general Danish population of 20,456 persons
| Diagnostic group | No. (%) of S. Typhimurium patients | No. (%) in the general population | Severity score (weight) in comorbidity index |
|---|---|---|---|
| Lymphoma or leukemia | 19 (0.9) | 23 (0.1) | 3.40 |
| Metastatic cancers | 8 (0.4) | 19 (0.1) | 2.02 |
| Liver disease | 10 (0.5) | 35 (0.2) | 1.97 |
| Tuberculosis | 0 | 13 (0.1) | 1.78 |
| Movement disorders and epilepsy | 4 (0.2) | 40 (0.2) | 1.56 |
| Diabetes | 44 (2.2) | 186 (0.9) | 1.50 |
| Renal disease | 31 (1.5) | 114 (0.6) | 1.37 |
| Inflammatory bowel disease | 39 (2.4) | 66 (1.7) | 1.34 |
| Other neurologic diseasesa | 12 (0.6) | 76 (0.4) | 1.32 |
| Hemoglobin abnormalities | 14 (0.7) | 62 (0.3) | 1.23 |
| Congestive heart failure | 22 (1.1) | 103 (0.5) | 1.22 |
aNeurologic or neuromuscular diseases other than Alzheimer's disease, multiple sclerosis, Parkinson's disease, Huntington's disease, and epilepsy.
Page created: July 15, 2010
Page updated: July 15, 2010
Page reviewed: July 15, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.